MedTrace Logo

LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)

NCT04041609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2023-07-25

Study results available
· View outcomes & findings →

Summary

This is a Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis.

Conditions

  • Chronic Sinusitis
  • Chronic Rhinosinusitis (Diagnosis)

Interventions

DRUG

LYR-210

A single administration of LYR-210 depot

OTHER

Sham comparator

Sham comparator

Sponsors & Collaborators

  • Lyra Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-09
Primary Completion
2020-03-25
Completion
2021-02-04
FDA Drug
Yes

Countries

  • Australia
  • Austria
  • Czechia
  • New Zealand
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04041609 on ClinicalTrials.gov